Condition
Ovary Neoplasms
Total Trials
5
Recruiting
0
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
33% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (3)
P 3 (1)
Trial Status
Terminated2
Active Not Recruiting1
Unknown1
Completed1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03842982Phase 3Active Not RecruitingPrimary
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)
NCT02432378Phase 1Terminated
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
NCT05059782Not ApplicableUnknown
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
NCT01535157Phase 1Terminated
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
NCT02582931Phase 1Completed
MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer
Showing all 5 trials